Nevro (NVRO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.65 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 37.80%. A quarter ago, it was expected that this maker of an electrical implant that treats leg and back pain would post a loss of $0.63 per share when it actually produced a loss of $0.43, delivering a surprise of 31.75%.Over the l ...

Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA GuidanceREDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance."Our worldwide revenue and adjusted EBITDA came in better ...

Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif., Oct. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research demo ...

REDWOOD CITY, Calif., Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. The company will also host a conference call beginning at 1:30 p.m. PST (4:30 p.m. EST) to discuss its financial results. The live webcast and replay of the conference call w ...

Nevro (NVRO) is well-poised for growth in the coming quarters, courtesy of strength in Senza and diversification plans regarding product portfolio. The optimism, led by a decent second-quarter 2024 performance and continued focus on research and development activities, is expected to contribute further. However, concerns regarding softness in the spinal cord stimulation (SCS) market and dependence on thirdparty payers persist. This Zacks Rank #3 (Hold) company's shares have lost 74.9% in the year-to-date pe ...

Nevro (NVRO) recently announced the FDA clearance and limited market release of HFX iQ with HFX AdaptivAI, a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system. HFX AdaptivAI uses artificial intelligence (AI) to provide responsive, individualized pain treatment in real-time by combining insights from over 100,000 patients and over 100 million data points. Likely Trend of NVRO Stock Following the News Following the announcement, shares of the company cl ...

HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real time* REDWOOD CITY, Calif., Sept. 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the U.S. Food and Drug Administration (FDA) approval and limited market release of HFX ...

REDWOOD CITY, Calif., Aug. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-andanswer) session at the Wells Fargo 2024 Healthcare Conference on Friday, September 6, 2024, beginning at 8:45 a.m. EDT. A live webcast of the session and a replay of the webcast will be available on the Eve ...

Justin Paget Shares of Nevro Corp. (NYSE:NVRO) have fallen to fresh lows after the company reset the guidance for the year. This did not really come as a complete surprise to me after I concluded that the company was causing back pains for investors in February of last year. After multiple boom-bust cycles for the shares in the past, shares arrived at a bust phase again. Unlike previous episodes, I believe that the growth story has been impaired after revenues have been stagnant for a while. While the resul ...

Nevro Corp. (NVRO) reported a loss per share of 53 cents in the second quarter of 2024, narrower than the year-ago quarter's loss of 69 cents. The metric beat the Zacks Consensus Estimate of a loss per share of 63 cents. Revenues in Detail Nevro registered worldwide revenues of $104.2 million in the second quarter, down 4.3% year over year on a reported basis and 4.2% on a constant-currency basis. The year-over-year decline was primarily due to the result of competitive pressures in the U.S. spinal cord sti ...